Coronary artery disease (CAD) was associated with a 35% increased risk of a prostate cancer (PCa) diagnosis among the 6,390 men taking part in the REDUCE trial, which evaluated whether dutasteride reduced PCa risk. Overall, 547 enrollees (8.6%) had a history of CAD.

Compared with men who had no heart disease, those with CAD were 24% more likely to be diagnosed with PCa two years into the REDUCE trial and 74% more likely four years into the study, Stephen J. Freedland, MD, and colleagues reported in Cancer Epidemiology, Biomarkers & Prevention.